Please assess the completion status of the following clinical trial:

Trial Title: Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and females aged 18-85 years who have given written informed consent.~* Subjects with a body mass index within 15-35 kg/m2 (Quetelet's index).~Exclusion Criteria:~* Subjects with history or evidence of keloid scarring.~* Subjects with tattoos or previous scars within 3cm of the area to be incised.~* Subjects who had surgery in the area to be incised within one year of the first dosing day.~* Subjects with history of a bleeding disorder or who were receiving anti-coagulant or anti-platelet therapy.~* Subjects with evidence of any past or present clinically significant disease that may affect the endpoints of the trial.~* Subjects with a clinically significant skin disorder that was chronic or currently active.~* Subjects with any clinically significant medical condition or history that would impair wound healing.~* Subjects with history of hypersensitivity to any of the drugs or dressings used in this trial.~* Subjects taking, or who have taken, any investigational product or who had participated in a clinical trial in the three months prior to first trial dose administration.~* Subjects taking regular, continuous, oral corticosteroid therapy.~* Subjects undergoing investigations or changes in management for an existing medical condition.~* Subjects with a history of drug abuse, or with a positive drugs of abuse test for cocaine, amphetamines, methamphetamines, opiates or benzodiazepines during the screening period.~* Subjects who, in the opinion of the investigator, were unlikely to complete the trial for whatever reason.~* Subjects who had any clinically significant neurological impairment or disease.~* Subjects with any active infection.~* Subjects who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).